rHA that make RIV4 unique from conventional vaccines, and how
these features help to maximise vaccine performance. Notably,
the beneÔ¨Åts of this manufacturing process can be extended to
other viral targets, such as COVID-19, where the preservation of
conserved epitopes is critical for imparting cross-protection
against a constantly evolving and mutating virus.